05/02/2026
Agitation in Alzheimer’s is one of the hardest symptoms families deal with… and for a long time, we’ve had very limited options.
A new FDA approval for Auvelity could change that.
This is the first non-antipsychotic approved for agitation in Alzheimer’s, which is a big shift in how we think about treatment and safety in this population.
Does it replace everything we’ve been doing? No.
But it does give us another option… and that matters.
If you’re a caregiver or provider, this is definitely something to have on your radar.
Have you seen agitation in a loved one with dementia? What has helped the most?